Our use of cookies

We use necessary cookies to make our site work.

For more detailed information about the cookies we use, see our Cookie Policy.


Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Therapy Areas in Europe

Good health and wellbeing is a universal aspiration, and we continue to seek ways to help patients in achieving better health and a better quality of life. In Europe our pharmaceutical business employs over 550 people, all of whom channel their energy into exploring solutions that we hope will make a difference to patients’ lives. We aim to help people with diseases that range from those affecting millions to those that affect relatively few. The health and wellbeing of patients is our primary focus, and we put the needs and views of patients, carers and healthcare professionals at the heart of the work we do. We aim to help patients in the following therapy areas: neuroscience, nephrology, haemato-oncology and endocrinology.

Neuroscience

For over 30 years, we have worked in the area of mental health, focusing on treatments for schizophrenia and bipolar conditions. We work closely with Lundbeck and Sunovion to bring new treatment options to the millions of people affected by mental ill health across Europe.

Haemato-oncology

With our partner Astex (acquired by Otsuka in 2013), we are currently focusing on haematological malignancies, such as acute myeloid leukaemia.

Digital Innovation

We are exploring how digital health technology may provide holistic health solutions for patients, carers and healthcare professionals.

Nephrology

We work with patients and healthcare professionals to increase awareness of kidney disease including autosomal dominant polycystic kidney disease (ADPKD). Together, with Aurinia, we are exploring treatment options for patients with Lupus Nephritis.

Specialty

We have been conducting research to identify medicines that help people affected by hormone-related conditions. One such condition is hyponatraemia which is abnormally low levels of sodium in the blood.

 

Date of preparation: June 2023 | Reference NOR-NPR-2300004

This website is for all those with an interest in Otsuka Pharmaceutical in the Nordics and BeNeLux.